Kidul-P Capsule DR contains a combination of Pregabalin 75 mg and Duloxetine 20 mg, formulated for the management of neuropathic pain and generalized anxiety disorders. Pregabalin, an anticonvulsant and analgesic agent, modulates calcium channels to reduce neurotransmitter release, thereby alleviating neuropathic pain and seizure activity. Duloxetine, a serotonin-norepinephrine reuptake inhibitor (SNRI), enhances central nervous system neurotransmission by increasing serotonin and norepinephrine levels, contributing to its efficacy in treating depression, anxiety, and chronic pain conditions. The delayed-release formulation ensures a controlled release of active ingredients, optimizing therapeutic outcomes and minimizing gastrointestinal side effects. Kidul-P Capsule DR is indicated for patients requiring combined therapy for neuropathic pain associated with diabetic peripheral neuropathy, fibromyalgia, or generalized anxiety disorder where monotherapy is insufficient. Dosage should be individualized based on clinical response and tolerability, with careful monitoring for adverse effects such as dizziness, somnolence, dry mouth, and gastrointestinal disturbances. Caution is advised in patients with hepatic or renal impairment, and gradual dose adjustments are recommended to mitigate withdrawal symptoms. Concomitant use with other central nervous system depressants should be approached cautiously. Kidul-P Capsule DR should be prescribed by healthcare professionals with consideration of patient-specific factors to ensure safe and effective treatment.